









Markets
/
Stocks
/
nasdaq-tenx
/

Tenax Therapeutics Inc

TENX

14.070USD

-0.900-6.01%

Market hours （ET）Quotes delayed by 15 min

514.44Market Cap

LossP/E TTM



Tenax Therapeutics Inc

14.070

-0.900-6.01%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Tenax Therapeutics Inc

Currency: USD Updated: 2026-03-27

Key Insights

Tenax Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 28.75.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tenax Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

11 / 391

Overall Ranking

70 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Tenax Therapeutics Inc Highlights

StrengthsRisks

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -11.11, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 6.62M shares, increasing 23.20% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 125.58K shares of this stock.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

28.750

Target Price

+92.05%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Tenax Therapeutics Inc is 6.95, ranking 161 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.95

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Tenax Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Tenax Therapeutics Inc is 8.79, ranking 20 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -11.11, which is -135.12% below the recent high of 3.90 and -121.36% above the recent low of -24.59.

Score

Industry at a Glance

Previous score

8.79

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Tenax Therapeutics Inc is 9.20, ranking 10 out of 391 in the Biotechnology & Medical Research industry. The average price target is 23.00, with a high of 30.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

9.00

Change

0.2

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Strong Buy

Current Rating

28.750

Target Price

+92.05%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Tenax Therapeutics Inc

TENX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Tenax Therapeutics Inc is 8.99, ranking 26 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 17.32 and the support level at 11.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.02

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.171

Buy

RSI(14)

58.166

Neutral

STOCH(KDJ)(9,3,3)

47.929

Buy

ATR(14)

1.450

Low Volatility

CCI(14)

56.893

Neutral

Williams %R

32.124

Buy

TRIX(12,20)

0.685

Sell

StochRSI(14)

94.926

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

14.274

Sell

MA10

14.529

Sell

MA20

13.550

Buy

MA50

13.426

Buy

MA100

11.827

Buy

MA200

9.091

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Ikarian Capital LLC

967.60K

Morgan Stanley & Co. LLC

174.27K

-0.28%

Perceptive Advisors LLC

439.14K

Invus Public Equities Advisors, LLC

427.14K

+21.20%

Point72 Asset Management, L.P.

Star Investors

339.63K

Dellora Investments LP

351.07K

RTW Investments L.P.

378.35K

Boothbay Fund Management, LLC

352.21K

BVF Partners L.P.

339.55K

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tenax Therapeutics Inc is 2.98, ranking 177 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.